Frazier Lifesciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses or entities in the biotechnology sector. The company was incorporated in 2020 and is based in Seattle, Washington.
IPO Year: 2021
Exchange: NASDAQ
Website: frazierlifesciencesacquisition.com
| Date | Price Target | Rating | Analyst |
|---|
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James "Jamie" Topper, M.D., Ph.D., to its Board of Directors. Dr. Topper currently serves as a Managing Partner at Frazier Life Sciences, which invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. He is also the Chairman and Chief Executive Officer of Frazier Lifesciences Acquisition Corporation (NASDAQ:FLAC). In addition to those leadership roles, he
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James "Jamie" Topper, M.D., Ph.D., to its Board of Directors. Dr. Topper currently serves as a Managing Partner at Frazier Life Sciences, which invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. He is also the Chairman and Chief Executive Officer of Frazier Lifesciences Acquisition Corporation (NASDAQ:FLAC). In addition to those leadership roles, he
Frazier Healthcare Partners announced today the promotion of four Life Sciences team members: Jamie Brush, M.D., to General Partner and Portfolio Manager, David Topper to Partner, Capital Markets, Liz Park to Principal, Investor Relations, and Joe Cabral to Senior Associate. Dr. Brush joined the Frazier Life Sciences team in 2016 and co-leads Frazier's public equity investment strategy. He is the co-portfolio manager for Frazier Life Sciences Public Fund, an $830 million long-only fund that invests in small- and mid-cap public biotech companies. He led Frazier's public investments in Trillium Therapeutics (NASDAQ:TRIL, pending acquisition by Pfizer))), Translate Bio (NASDAQ:TBIO, acquired
Frazier Lifesciences Acquisition Corporation (NASDAQ:FLAC) (“FLAC”), a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, announced today that its shareholders voted to approve the proposed business combination (the “Business Combination”) with NewAmsterdam Pharma Holding B.V. (“NewAmsterdam”), a late clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases. More than 90% of the votes cast at the Extraordinary General Meeting of Shareholders (the “General Meeting”) were cast in favor of the previously announced business combination. FLAC shareholders also voted to approve all
Although US stocks closed higher on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Frazier Lifesciences Acquisition The Trade: Frazier Lifesciences Acquisition Corporation (NASDAQ:FLAC) 10% owner Sharon Rose Sha
– Leading institutional investors commit approximately $235 million through an oversubscribed and upsized private investment in public equity ("PIPE") led by Frazier Healthcare Partners and Bain Capital Life Sciences – – Total proceeds expected to bring pro forma cash balance to at least $470 million; expected to extend cash runway of NewAmsterdam through 2026, funding all expected pre-approval milestones for lead candidate obicetrapib, includingreadouts of Phase 3 PREVAIL study, a global cardiovascular outcomes trial ("CVOT") and two other pivotal Phase 3 studies – – NewAmsterdam's lead therapeutic candidate, obicetrapib, is a next-generation oral, low-dose and once-daily CETP inhibitor f
4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)
4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)
4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)
4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)
4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)
4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)
3 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)
4 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)
3 - Frazier Lifesciences Acquisition Corp (0001828326) (Issuer)
SC 13G/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
SC 13G/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
SC 13D/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
SC 13D/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
SC 13G - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
SC 13D - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
SC 13G - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
SC 13D/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
SC 13G - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
SC 13G/A - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
15-12G - Frazier Lifesciences Acquisition Corp (0001828326) (Filer)
8-K - Frazier Lifesciences Acquisition Corp (0001828326) (Filer)
25-NSE - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
25-NSE - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
25-NSE - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)
8-K - Frazier Lifesciences Acquisition Corp (0001828326) (Filer)
10-Q - Frazier Lifesciences Acquisition Corp (0001828326) (Filer)
DEFM14A - Frazier Lifesciences Acquisition Corp (0001828326) (Filer)
10-Q - Frazier Lifesciences Acquisition Corp (0001828326) (Filer)
425 - Frazier Lifesciences Acquisition Corp (0001828326) (Subject)